The efficacy and acceptability of nebivolol 5 mg and response rate (70% vs 55%; P ‫؍‬ 0.002). The trough-topeak sitting diastolic ratios also favoured nebivolol enalapril 10 mg, each given once daily, were compared in essential hypertension in a multicentre, randomised, (84% vs 60%, P ‫؍‬ 0.002). Nebivolol, but not enalapril, slightly but significantly lowered heart rate. Both drugs double-blind trial over 3 months. For the index predeclared variable, sitting diastolic pressure at trough were well-tolerated, although enalapril was accompanied by a significantly higher incidence of drug level, nebivolol achieved greater falls in pressure (؊12.3 vs ؊9.9 mm Hg; P ‫؍‬ 0.009) and a higher coughing.
Introduction
trial procedures, and those entering were required Nebivolol is a highly cardioselective ␤-blocker with to give informed consent. These subjects were then vasodilating properties; it acts in part via the Lgiven single-blind placebo for 1 month. Any prearginine/nitric oxide pathway; it is devoid of intrinsic sympathomimetic activity. [1] [2] [3] [4] [5] [6] [7] [8] [9] Nebivolol has been improved left ventricular function when given to ¼ heart failure requiring treatment; patients with cardiac impairment and was well tol-¼ valvular disease of haemodynamic significance; erated in heart failure.
14-18 The present study com-¼ myocardial infarction or cerebrovascular accident within the prises a double-blind randomised parallel-group last 6 months; ¼ insulin-dependent diabetes;
comparison of nebivolol with the angiotensin-¼ sensitivity or significant adverse reaction to beta-blockers or converting enzyme (ACE) inhibitor enalapril in ACE-inhibitors; essential hypertension. ¼ significant renal (urine protein Ͼ trace, creatinine Ͼ2.2 mg/dl or Ͼ200 mol/l) or hepatic (alamine-amino transferase and/or aspartate-amino transferase Ͼ2× the
Patients and methods
upper normal limit, total bilirubin Ͼ1.5× the upper normal limit) disease;
The trial was conducted in 30 centres variously in At week 2 of the run-in period, and at the end of the double-blind comparison, routine urine testing at 2 and 4 weeks of the placebo period. Those with a diastolic BP (DBP) above 114 mm Hg at 2 weeks was done, and blood samples were taken for routine haematological and biochemical tests; whilst in a were allocated to active double-blind therapy forthwith. Untreated patients whose diastolic was below subset of centres, from a total of 154 patients, a further 10 ml of blood was collected for more 95 mm Hg at the 4th week of placebo did not proceed further. Trial subjects were randomly assigned detailed analysis of lipids (total cholesterol, highdensity and low-density lipoproteins (HDL and in blocks of 12 to receive orally, once-daily and double-blind, either nebivolol 5 mg or enalapril LDL) and triglycerides). Twelve-lead electrocardiography was performed 10 mg. Visits during this comparison period were scheduled for weeks 2, 4, 8 and 12. After 3 months at week 2 of the run-in period, at the end of the double-blind comparison, and at the end of the runof double-blind therapy the patients in both treatment groups were reallocated randomly to a 'runout period.
Patients were free to discontinue the trial at any out' period of 1 month, double-blind on either placebo or a continuation of their existing nebivolol or time. They could also be withdrawn for any reason at the discretion of the investigator. They were to be enalapril therapy. Visits were scheduled at weeks 2 and 4 of the run-out period.
withdrawn if the sitting diastolic pressure exceeded 119 mm Hg after 2 weeks, or 114 mm Hg after 4 Medication comprised tablets identical in size, colour, and taste, containing either placebo, nebivoweeks of double-blind treatment, or if the treatment code was broken for any reason. The trial was lol 5 mg, or enalapril 10 mg. Throughout, one tablet was to be taken once daily at breakfast, except when approved by the ethical supervisory committee of each participating centre. the subjects attended for BP assessment, when medication was omitted until this had been completed. At the randomisation ('baseline') and at the comStatistics pletion of the 3 months comparison period, BP was also measured 2-3 h after drug ingestion, ie, at times
The pre-declared index variable to be assessed was sitting diastolic pressure at trough drug level. The likely to be close to peak plasma levels.
19-22 Compliance was assessed by tablet count at the end of shift from baseline of sitting DBP at trough level was defined as the primary measurement. Assuming a the comparison period. Systolic and diastolic BPs (respectively taking Korotkoff phases 1 and 5) were difference of at least 4 mm Hg with a standard deviation of 12 mm Hg in this measurement between the measured at all scheduled visits employing a standard sphygmomanometer. The cuff was required to two drug groups, with 80% power and 5% twotailed significance, at least 142 patients were needed be at least 30 cm long and 13 cm wide; if the arm circumference exceeded 34 cm, an appropriate per treatment group. Therefore a minimum of 320 patients, 160 per group, were planned to be entered. larger cuff was used. In each patient such measurements were made by the same investigator (or mem-
The statistical analysis was performed according to the intent-to-treat principle, ie, on all patient's ber of the investigator's staff) in the same room at the same time of day. Three consecutive sitting randomised, regardless of their compliance with the protocol. All statistical tests reported are two-tailed pressures were taken after the patient had rested for at least 5 min; the last value was used for decisionand a P-value р0.05 was considered significant, unless specified otherwise. If for any reason a making and for statistical analysis, except for suspected protocol deviations, where all readings were patient failed to complete the trial as planned, the last available data were taken as 'end-point'. The considered. BP was further measured once after the patient had stood for 2 min. At the first visit BP was end-point evaluation was considered as the primary time point. determined in both arms; if a difference of more than 4 mm Hg was found, the arm with the higher pressResponse to treatment was defined as a decrease in sitting trough DBP to 90 mm Hg or below, or a ure was subsequently always used, otherwise the right arm was employed throughout.
decrease in diastolic pressure of at least 10 mm Hg vs baseline, if the treated diastolic values remained Heart rate was recorded immediately after the measurement of both sitting and standing BP on all above 90 mm Hg. Odds ratios were calculated to compare the response rates of the nebivolol group occasions. Patients were weighed, partially clothed, at each visit.
with the enalapril group; additionally, 2 tests were performed on the number of responders. Trough-toAny adverse events were recorded either if mentioned spontaneously by the patient or in response peak ratio was calculated for the sitting DBP as follows:
19 to the standard question, 'Has treatment upset you in any way?' Positive events were those recorded in trough/peak = ⌬ DBP trough/⌬ DBP peak response to the further standard question, 'Did you experience any beneficial effect from treatment? ' where ⌬ DBP = shift in DBP from baseline (ie, at randomisation) to week 12 of the double-blind treatSymptoms were additionally assessed at the end of the run-in period, and at the end of the doublement. The individual items of the symptom questionblind period comparison period, using a standard questionnaire 10 which rated increasing severity of naire and the total symptom severity score, defined as sum of all items, were presented descriptively. 35 symptoms commonly occurring during treatment nebivolol and enalapril respectively. Despite the slightly lower initial value for the nebivolol group, Four hundred and nineteen patients entered the trial shifts from baseline to the end of the comparison proper, that is substantially more than the planned period significantly favoured nebivolol (−12.3 minimum. Of these 208 were randomised to nebivomm Hg vs −9.9 mm Hg; P = 0.009) as being the more lol and 211 to enalapril. Their characteristics, which effective drug. The percentages of responders are detailed in Table 2 , were broadly similar (defined as in the Methods section) at week 12 of between the two treatment groups.
the comparison were 70% on nebivolol vs 55% on enalapril (P = 0.002).
Patient drop-outs
The trough-to-peak ratios for sitting diastolic pressure at 3 months of double-blind treatment were In total, 65 patients did not complete the trial (29 83 .9% for nebivolol and 60.1% for enalapril nebivolol and 36 enalapril; 54 in the comparison (P = 0.02). Neither drug had an appreciable orthoperiod and 11 in the run-out phase). During the comstatic hypotensive effect. parison period the main reason for withdrawal was
Thus with the present design, and with the doses inefficacy (six nebivolol and 17 enalapril) or adverse employed, nebivolol performed rather better than events (nine nebivolol and 12 enalapril). During the enalapril in lowering BP. The superior trough-torun-out phase, the main reason for dropping out was peak ratio indicated that once daily nebivolol gave an intercurrent event.
more even control of BP over 24 h. With neither drug was the antihypertensive response influenced Compliance with therapy by age or gender. By tablet count, all except 11 patients took more than 80% of their medication during the run-in; during the comparison period, all except seven nebivoHeart rate lol and three enalapril patients took more than 80%;
Heart rates were similar in the two treatment groups and during the run-out 19 patients took less than at baseline. Throughout the periods of active ther-80% (six remaining on nebivolol, three randomised apy, heart rate was significantly lower with nebivofrom nebivolol to placebo, six remaining on enalaplol than enalapril, the respective mean ± s.e.m. ril, and four randomised from enalapril to placebo).
values at the 12th week of comparison, sitting, being 68.7 ± 0.69 vs 74.5 ± 0.81; P Ͻ 0.001.
Blood pressure

Details of the trough values for sitting and standing systolic and diastolic BPs during the comparison
Body weight and run-out phases are given in Figures 1 and 2 . Both drugs substantially lowered arterial pressure.
Neither during the run-in period nor during the comparison were any significant differences in body The primary declared criterion of evaluation was the sitting diastolic pressure at trough drug level. At weight seen between nebivolol and enalapril, the respective means remaining between 74.8 and baseline, this value was slightly but significantly lower (mean 0.9 mm Hg, P = 0.032) in the nebivolol 75.8 kg. Symptom assessment nebivolol and seven enalapril). During the comparison period nine nebivolol and 12 enalapril patients From baseline to the end of the comparison period, stopped treatment permanently because of adverse the mean total symptom score did not deteriorate in events. either group, nor did the mean scores deteriorate for any of the individual symptoms. In most patients there were about as many improvements as deterioRoutine laboratory tests rations. Only for cough, and then only with enalaThroughout, no consistent or relevant changes were pril, did deteriorations (n = 48) outnumber improveseen in any of the routine urinary, haematological, ments (n = 18) during the comparison period in or biochemical tests. more than 10% of the patients per group.
Plasma lipids Positive events
The incidence of positive experiences was similar As mentioned above, these data were obtained in a subset of patients (80 nebivolol and 74 enalapril). in both treatment groups, being reported by 53% of the nebivolol and 55% of the enalapril subjects dur-
The plasma levels of total cholesterol, high and low density lipoproteins (HDL/LDL) remained constant ing the comparison period. For both groups, the most frequently mentioned positive experience was throughout. For plasma triglycerides the nebivolol group showed a rise in the mean concentration from enhanced general well-being.
164.1 mg/dl at the end of the run-in to 194.3 mg/dl at the end of the 12 weeks comparison period, vs a Adverse events fall from 162.3 to 149.1 mg/dl in the enalapril group. These differences were due to marked increases The total of reported adverse experiences in at least five patients throughout the double-blind period of occurring in just two patients in the nebivolol group, respectively from 370 to 1067 and from 170 to 695 the trial is shown in Table 3 .
The adverse events most often reported during the mg/dl. When these outliers are omitted, the triglycerides levels in the nebivolol group rose from 161.4 double-blind comparison period were headache (24 nebivolol and 25 enalapril), cough (six nebivolol mg/dl at baseline to 175 mg/dl at the end of the comparison period. and 21 enalapril; P = 0.0045), and paraesthesiae (13 The definitive dose of nebivolol (5 mg), was superior index measurement, the sitting diastolic pressure at Cough 6 21 trough drug level, both concerning the extent of BP Fatigue 6 4 Diarrhoea/nausea 6 6 reduction and the response rate.
Chest pain 6 5 There was a considerably higher calculated Dizziness 5 7 trough-to-peak BP ratio with nebivolol than with predominate in the population. 20 Peak plasma levels of enalaprilat, the active metabolite of enalapril, are found around 4 h after ingestion. 21, 22 It is thus possible that with the assessment time chosen after drug ingestion, the peak plasma levels had slightly Electrocardiogram passed with nebivolol, and, by contrast had not been achieved with enalaprilat. However, as mentioned, No unexpected systematic changes were observed in nebivolol showed the better antihypertensive effect the electrocardiogram. At the end of the comparison plus more numerous responders at trough. Thus any period, in comparison with baseline, the nebivolol tendency to underestimate the true peak effect of group showed a decrease in heart rate, QRS, and enalapril would have favoured a higher calculated QTc and an increase in PQ and QT; while in the enalapril group heart rate and QTc decreased.
trough-to-peak ratio with that drug. Therefore the 
